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SEASONAL MALARIA ATTACK RATES IN INFANTS AND YOUNG CHILDREN IN
NORTHERN GHANA
J. KEVIN BAIRD, S. OWUSU AGYEI, GREGORY C. UTZ, KWADWO KORAM, MAZIE J. BARCUS, TREVOR R. JONES,
DAVID J. FRYAUFF, FRED N. BINKA, STEPHEN L. HOFFMAN, AND FRANCIS N. NKRUMAH
Naval Medical Research Center, Silver Spring, Maryland; Navrongo Health Research Centre, Navrongo, Ghana; U.S. Naval Medical
Research Unit No. 3, Cairo, Egypt; Noguchi Memorial Institute for Medical Research, Accra, Ghana

Abstract. The incidence density of infection and disease caused by Plasmodium falciparum in children aged six to 24
months living in the holoendemic Sahel of northern Ghana was measured during the wet and dry seasons of 1996 and
1997. At the beginning of each season, a cohort composed of 259 and 277 randomly selected children received supervised
curative therapy with quinine and Fansidar威 and primaquine for those with normal glucose-6-phosphate dehydrogenase
activity. The 20 weeks of post-therapy follow-up consisted of three home visits weekly and examination of Giemsastained blood films once every two weeks. Blood films were also taken from children brought to clinic with illness. The
incidence density of parasitemia after radical cure was 4.7 infections/person-year during the dry season and 7.1 during
the wet season (relative risk ⳱ 1.51, 95% confidence interval [CI] ⳱ 1.25–1.81; P ⳱ 0.00001). Although the mean
parasitemia count at time of reinfection in the dry season (3,310/l) roughly equaled that in the wet season (3,056/l; P
⳱ 0.737), the risk ratio for parasitemia > 20,000/l during the wet season was 1.71 (95% CI ⳱ 1.2–2.4; P ⳱ 0.0025). The
risk ratio for parasitemia > 20,000/l with fever during the wet season was 2.45 (95% CI ⳱ 1.5–4.1; P ⳱ 0.0002). The
risk ratio for anemia (hemoglobin < 8 g/dl) at first post-radical cure parasitemia showed no difference between seasons
(1.0; 95 % CI ⳱ 0.73–1.4; P ⳱ 0.9915). We did not see seasonal differences in anemia known to exist in this region,
probably because the longitudinal cohort design using first parasitemia as an end point prevented the subjects from
developing the repeated or chronic infections required for anemia induction. These findings bear upon the design of
malaria drug and vaccine trials in holoendemic areas.
density of infection. Thus, it is difficult to begin to assign
optimal exposure thresholds, i.e., incidence densities that induce protective immunity from cerebral malaria but below
those leading to severe anemia.
We measured the incidence density of infection by P. falciparum in infants and young children residing in holoendemic northern Ghana, where seasonal severe anemia is the
major cause of malaria-related morbidity.10 Incidence density
was measured as the post-radical cure attack rate for P. falciparum parasitemia. This work provides relatively precise
measures of incidence that may be linked to established patterns of disease risk in the region, i.e., high risk of severe
anemia among infants and young children. These studies provide a foundation for planning intervention trials in the region, and contribute to the process of assigning risk to defined
degrees of exposure to infection.

INTRODUCTION
The risk of infection by Plasmodium falciparum within endemic regions varies widely across geographic and seasonal
parameters. If one gauges risk as the time to reach a proportion of 1.0 (i.e., 100% of those at risk have been infected),
holoendemic areas of sub-Saharan Africa often yield estimates of just 8–12 weeks.1–3 This reflects an incidence density
of approximately five infections/person-year. In contrast, the
time to 100% risk in most of the endemic regions of the
Amazon basin ranges between five and 10 years, or an incidence density of approximately 0.1 infections/person-year.4
Risk of infection has been linked to patterns of morbidity
and mortality caused by P. falciparum.5–9 Severe anemia represents the primary cause of malaria-related death where the
highest risk of infection prevails, while death due to cerebral
malaria predominates in areas where infection risk is lower.
Naturally acquired immunity in older children and adults in
holoendemic Africa effectively prevents either outcome in
those groups, but degree of exposure in infants and small
children defines risk of specific disease outcomes. Protection
from cerebral malaria requires the relatively heavy, uninterrupted exposure such as occurs through the Sahel of subSaharan Africa, but this carries risk of severe anemia.
The threshold of exposure for protection from cerebral malaria versus that for significant risk of severe anemia is not
known. The argument has been made that diminishing risk of
severe anemia by reducing exposure to infection, e.g., with
mosquito bed nets, may increase susceptibility to cerebral
malaria.6 However, the basis of that argument lies in empirical observations. It remains possible that an exposure level
ideal for maintaining protection against cerebral malaria lies
well below the exposure of risk for severe anemia. This represents a critical question in the context of control strategies
intended to diminish disease and death caused by malaria,
especially in sub-Saharan Africa. Few studies in the region
have linked disease risks to quantitatively measured incidence

MATERIALS AND METHODS
Study site. The Kassena-Nankana District in the Upper
East Region of northern Ghana in western Africa (Figure 1)
served as the study site. Approximately 140,000 people reside
in this district of typical Guinea savanna with sharply distinct
wet and dry seasons (Figure 2). Most residents practice subsistence farming, predominantly raising livestock and growing
millet. They live within traditional compounds of extended
family groups. An on-going census of the population conducted by the Navrongo Health Research Centre tracks
births, deaths, migration, and other features on a quarterly
basis (the Navrongo Demographic Surveillance System,
NDSS). Malaria is holoendemic11 and is the most important
cause of morbidity and mortality.12
Study subjects. Two cohorts were recruited, one at the beginning of the dry season in November 1996 and another at
the beginning of the wet season in May 1997. Children between the ages of six and 24 months were eligible for participation. They were selected for recruitment by stratification of
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FIGURE 1.
Ghana.

Location of the Kassena-Nankana District in northern

the study site followed by a randomized selection of 15 index
clusters of family compounds among the four geographic regions of the district recognized by the NDSS. The number of
subjects recruited from each zone represented a sample
weighted according to the proportional contribution to the
entire population of the district.
Meetings were held with tribal and family group leaders
representing the selected index compounds. The rationale,
methods, risks, and benefits of the study were explained and
questions were addressed. The assent of these leaders represented a key element of the process of informed consent
within the cultural context of northern Ghana. We nonetheless repeated the process with individual volunteers at enrollment in accordance with U.S. Navy regulations concerning
the use of human subjects of medical research (SECNAVINST 3900.39B) and those of the Ministry of Health,
Republic of Ghana. The verbal explanation and the written
informed consent forms were in the native languages of the
subjects (Kasem or Nankam).
Each index cluster had a target of 19 study subjects. However, variability in the number of eligible subjects per compound required a uniform strategy for reaching beyond the
randomly identified index cluster. When the index compound
failed to yield the target of 19 subjects, the closest compound
to the east served as a secondary target for recruitment. If
necessary, the process was repeated in adjacent compounds to
the north, west, and south, always in that order. The population-weighted random selection of index compounds among
zones assured all eligible children in the district had an equal
probability of selection.
Mothers indicating a willingness to participate in the study
were transported with eligible children to an enrollment station. During the two week enrollment phase of each cohort,
approximately 40 subjects were screened daily by the research
team. Children with peripheral blood hemoglobin concentra-

FIGURE 2. Maximum, minumum (solid dots, dotted lines) or
mean (squares, solid line) monthly rainfall in the Kassena-Nankana
District in northern Ghana between 1978 and 1995, and monthly
rainfall during 1996 (✕) and 1997 (䡬). The arrows at November and
May indicate enrollments for the dry season and wet season cohorts,
respectively.

tions > 5.9g/dl and free of disease requiring hospitalization
were enrolled. Among the 349 children screened at the beginning of the dry season (end of wet season), 94 were excluded due to severe anemia. These severely anemic children
were taken to the district hospital for treatment. Among the
286 children screened at the beginning of the wet season, 275
were enrolled; only four of 11 exclusions had severe anemia.
The report by Koram and others10 details the marked differences in prevalence of severe anemia between these two randomly selected cohorts. Table 1 lists the statistical summary of
each cohort.
Radical cure. Radical cure started on the day following enrollment. Subjects received quinine sulfate (Cox Pharmaceuticals, Fort Lee, NJ, or Royce Laboratories, Miami, FL; 10
mg/kg, three times a day for four days), followed by Fansidar威
(F. Hoffmann LaRoche Pharmaceuticals, Basel, Switzerland;
half a tablet for 5–10 kg of body weight, and one tablet for >
10 kg, single dose). Subjects testing normal for glucose-6phosphate dehydrogenase (G6PD, assay by NADP+ spot test;
Sigma Chemical Co., St. Louis, MO) received 0.3 mg of primaquine base per kilogram of body weight (primaquine phosTABLE 1
Comparison of dry and wet season cohorts at enrollment of infants
and small children in the Kassena-Nankana District of northern Ghana
Feature*

Dry season cohort

Wet season cohort

P

Sample size
Male : Female
Mean age (months)
Mean weight (kg)
% G6PD deficient
Parasitemia

259
0.9923
14.98
7.97
6.95
69%

277
1.022
14.83
7.80
9.71
52%

0.865
0.749
0.211
0.247
0.001

* G6PD ⳱ glucose-6-phosphate dehydrogenase.
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phate; Sanofi Winthrop Pharmaceuticals, New York, NY)
once a day for 14 days. A licensed pharmacist prepared all of
these medications in flavored syrups. A trained field health
worker employed by the research team used a syringe to dispense volumes of medicated syrup prescribed by the team
physician. Only six of 536 subjects (1.1%) missed two or more
of the 27 doses. Eighteen of 259 subjects (6.9%) in the dry
season cohort and 27 of 277 subjects (9.7%) in the wet season
cohort tested positive for G6PD deficiency and primaquine
was withheld from their radical cure.
Laboratory procedures. We used the qualitative NADP+
spot test with modifications to the procedure recommended
by the manufacturer (Sigma Chemical Co.). Batches of 30
specimens were tested using a single positive control spot
(G6PD-deficient control; Sigma Chemical Co.). Prescribed
mixtures of blood (10 l), buffer, and G6PD substrate were
incubated at room temperature (approximately 30°C) for 10
min, blotted onto filter paper, air dried, and read in a darkened room under ultraviolet light. We did not use a 37°C
water bath or readings at timed intervals as prescribed by the
kit manufacturer. Subjects diagnosed as G6PD-deficient produced blots that failed to fluoresce to the same extent as most
other blots (i.e., the negative control), and to the same extent
as the known G6PD-deficient sample on the same blotter (the
positive control).
Hemoglobin levels were measured using the Hemocue威
(HemoCue AB, Ängelholm, Sweden) system. A microcuvette preloaded with stable reagents withdrew approximately 10 l of blood from the site of puncture. It was immediately placed into a portable spectrophotometric instrument. Stable control cuvettes provided by the manufacturer
confirmed proper operation of the instrument. Axillary temperatures were obtained using digital thermometers placed
under the arm.
Thick and thin blood films were stained with Giemsa reagents in the usual manner and were read by an experienced
malaria microscopist on the day collected. Two hundred optical fields under 1,000× oil immersion magnification were
examined before a film was recorded as negative. Counts of
parasites in the thick film were based on the number of
asexual parasites per 200 white blood cells (WBCs). This
number was converted to parasites per microliter of whole
blood using a conversion multiple of 40 (assumes 8,000
WBCs/l).
Follow-up. A trained field health worker with at least a
secondary school education was assigned to each index compound for the 18 days of radical cure and the 20-week followup period. The field worker visited each compound within his
or her area three times per week to query mothers/guardians
of the health of their child. Complaint of illness prompted
transport of the mother and child to the district hospital for
examination by a physician, including a blood film examination for plasmodia. Every two weeks a blood film was collected whether or not the mother complained of illness in her
child. Children with malaria were treated with Lariam威 mixed
in syrup (mefloquine HCl; F. Hoffmann LaRoche Pharmaceuticals; 20 mg base/kg of body weight in a single dose).
Whether administered after an unscheduled visit to hospital
or after a routine blood film examination, therapy with mefloquine marked the endpoint of participation in this study.
The efficacy of mefloquine for therapy in these cohorts was
virtually complete (Baird JK and others, unpublished data).

Clinical analysis. Children presenting with signs of disease
(fever, anemia) and patent parasitemia were considered to be
ill with malaria. Although other diseases certainly occur in the
district, and we have not yet estimated the risk attributable to
malaria among febrile or anemic children, malaria infection
overwhelmingly dominates the burden of disease in these
communities. An important exception to this rule is epidemic
meningococcal meningitis, which did not occur during these
studies. Evidence of disease reported by the mother, including fever, rigors, or vomiting, when coupled with patent parasitemia were attributed to malaria. Although the lower limit
for permissible hemoglobin at enrollment was 6.0 g/dl, we
used a hemoglobin level < 8.0 g/dl to define anemia as a
disease endpoint in the presence of parasitemia.
Epidemiologic analysis. Incidence Density. Incidence density estimates the force of infection, or new infections per unit
person-time. The administration of radical cure allowed classification of post-treatment parasitemia as a new infection. In
the absence of cure, recrudescence and relapse confounds the
estimate. We used the direct method to measure incidence
density; the number of post-treatment parasitemias divided
by the sum of person-time at risk. Subjects no longer contributed person-time to the denominator after becoming parasitemic or when lost to follow-up.
The incidence density of other endpoints was measured.
Parasitemia with fever (axillary temperature > 99°F) or with
anemia (hemoglobin < 8.0g/dl) at parasitemia densities >
5,000/l, > 10,000/l, > 20,000/l, and > 50,000/l constituted
these endpoints. Subjects having parasitemia without the
specified outcome variable were designated as dropouts in
these estimates, i.e., contributing person-time to the denominator up to the time of unqualified parasitemia.
We used incidence densities to calculate the risk of an outcome in one group relative to the risk experienced by another
group using SPSS version 8.0 (SPSS, Inc., Chicago, IL). A
relative risk of 1.0 reflected no difference in the risk to the
two groups, and the distance from 1.0 (in either direction)
represented the degree of difference between the rates. We
calculated 95% confidence intervals (CIs) around the relative
risks as measures of the precision of our estimates. The significance of the difference between the rates was determined
using Fisher’s exact test or a chi-square test depending on
number of events within groups.
Cumulative incidence. Cumulative incidence expresses the
risk of an outcome over a defined period as a proportion. The
primary risk evaluated in this study was first parasitemia after
radical cure. We also calculated risk of high density parasitemia (> 20,000/l). The first 10 days following radical cure
were considered to be free of risk, and were excluded from
the denominator of the estimate of cumulative incidence. The
life table method using weekly intervals estimated cumulative
incidence. When calculating the risk of developing a parasitemia > 20,000/l, subjects developing parasitemias < 20,000/
l were treated as withdrawals, i.e., contributing to the denominator up to the interval in which they became parasitemic (assuming a mid-interval event for all subjects).
RESULTS
Radical cure. The prevalence of parasitemia at enrollment
was 69% and 52% in the dry and wet season cohorts, and this
probably accounted for much of the vomiting that occurred
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TABLE 2
Age-specific geometric mean Plasmodium falciparum parasite densities (95% confidence interval) in infants and small children in the
Kassena-Nankana District in northern Ghana
Age group (months)

A. Enrollment
<12
12–18
>18
All ages

Dry season cohort

1,515 (949–2,418)
811 (470–1,401)
1,084 (696–1,688)
1,112 (842–1,470)

B. Post-Radical Cure
<12
3,796 (2,161–6,667)
12–18
2,580 (1,461–4,555)
>18
3,564 (2,111–6,015)
All ages
3,310 (2,409–4,547)

Wet season cohort

P

925 (528–1,620)
1,169 (645–2,120)
1,150 (706–1,875)
1,099 (801–1,507)

0.194
0.376
0.860
0.911

1,704 (970–2,991)
5,131 (2,629–10,013)
3,716 (2,174–6,353)
3,056 (2,177–4,290)

0.061
0.127
0.913
0.737

during radical cure. Repeated vomiting (three or more episodes) occurred in 4.7% and 3.6% of subjects taking quinine
in the dry and wet season cohorts, respectively (P > 0.1).
After the single dose of Fansidar,威 0.8% and 6.2% of subjects
reported vomiting in the dry and wet season cohorts (P <
0.001). During the administration of primaquine in the dry
season and wet season cohorts, 4.6% and 6.8% of subjects
had repeated vomiting (P > 0.1). Despite the risk of vomiting,
531 of 537 subjects (98.9%) beginning radical cure completed
the regimen, and 530 had negative blood films on day 15 of
radical cure (> 99% efficacy).
Point measures. Enrollment. The two cohorts were virtually identical with respect to composition by sex, age, weight,
and frequency of G6PD deficiency (Table 1). The prevalence
of parasitemia at enrollment was significantly higher in the
dry season cohort (end of wet season) than in the wet season
cohort (end of dry season); 69% versus 52%; P < 0.0001.
However, there was no difference either overall or within
specific age groups in geometric mean parasite densities between wet and dry season cohorts at enrollment (Table 2A).
First Parasitemia. The density of first parasitemia after radical cure was also similar among age groups between the wet
and dry seasons (Table 2B). Infants < 12 months old in the dry
season cohort exhibited a mean parasite density after radical
cure that approached being significantly higher compared to
those in the wet season cohort (P ⳱ 0.061; Table 2B).
The prevalence of fever with first parasitemia was 31% in
the dry season cohort and 34% in the wet season (relative risk
⳱ 0.91, 95% CI ⳱ 0.69–1.18; P ⳱ 0.464). Only children 12–18
months old had a slightly higher risk of fever during the wet
season (relative risk ⳱ 0.67, 95% CI ⳱ 0.42–1.07; P ⳱ 0.083).
Incidence density. Figure 3 shows the incidence density of
infection among index compounds representing the sample
evaluated in the wet and dry season cohorts. The data do not
include 21 subjects that could not be retrospectively assigned
to an index compound. Only 11 of 15 index compounds (A
through K in Figure 3) appear in this analysis because proximate compounds were lumped together due to uncertainty
with original index assignment. All 15 index compounds were
represented among the 11 clustered compounds shown in Figure 3. Index compounds in the wet season cohort had incidence densities ranging from 6.42 to 10.4 per person-year (P
> 0.10, by the Mantel-Cox log rank test). Index compounds in
the dry season cohort had incidence densities ranging from
1.12 to 7.29 per person-year (P > 0.10). These data illustrate
the relatively uniform incidence of new infection among the

FIGURE 3. Incidence density among index compounds representing the sample population for the wet (solid bars) and dry (dashed
bars) season cohorts. Variance from the mean incidence density in
the wet season (solid line) and dry season (dashed line) among index
compounds was not significant (P > 0.10 and P > 0.10) by the MantelCox log rank test.

randomly selected index compounds in both the wet and dry
season cohorts.
Table 3 lists the incidence densities of new infection in the
wet and dry season cohorts. The table stratifies incidence
density according to parasite density and accompanying illnesses, i.e., with fever or anemia. Incidence density of any
parasitemia in the wet season was significantly higher than in
the dry season; 7.11 versus 4.71 infections/person-year (relative risk ⳱ 1.51, 95% CI ⳱ 1.25–1.81; P ⳱ 0.00001). The
relative risk was still higher when fever was included in the
endpoint; 1.46 versus 2.43 infections/person-year (relative risk
⳱ 1.66, 95% CI ⳱ 1.20–2.31; P ⳱ 0.0023). However, for
parasitemia with anemia, there was no difference in incidence
density between wet and dry season cohorts (relative risk ⳱
1.02, P ⳱ 0.9915).
The pattern of significant differences in incidence density
between any parasitemia, or those with fever but not anemia
in the wet and dry season cohorts, appeared at all strata of
parasite density (Table 3). In general, the greater the parasite
density, the greater the relative risk for that outcome in the
wet season cohort. Compared with the dry season, the risk of
having a febrile parasitemia of any density was 1.66 times
higher than that in the wet season. Similarly, the risk of
developing febrile parasitemia > 5,000/l, > 10,000/l, >
20,000/l, and > 50,000/l during the wet season was 1.92,
1.93, 2.45, and 4.33 times that in the dry season respectively.
The 95% CIs for all of these relative risks did not include 1.0,
and the P values were always < 0.0025. In contrast, the relative risk of parasitemia with anemia never produced 95% CIs
that excluded 1.0, and the P values were never < 0.33.

284

BAIRD AND OTHERS

TABLE 3
Incidence density of Plasmodium falciparum parasitemia post-radical cure in infants and small children in the Kassena-Nankana District of
northern Ghana
Dry season

Wet season

n

Incidence
density*

n

Incidence
density*

Relative
risk†

95% CI‡

P§

200
62
73

4.71
1.46
1.72

254
87
63

7.11
2.43
1.76

1.51
1.66
1.02

1.25–1.81
1.20–2.31
0.73–1.44

0.00001
0.00225
0.99147

Parasitemia >5,000/l
± fever, anemia
With fever¶
With anemia#

90
37
33

2.18
0.89
0.80

121
61
27

3.39
1.71
0.76

1.56
1.92
0.95

1.18–2.04
1.27–2.87
0.57–1.58

0.00146
0.00221
0.89733

Parasitemia >10,000/l
± fever, anemia
With fever¶
With anemia#

78
33
30

1.89
0.80
0.73

103
55
25

2.88
1.54
0.70

1.53
1.93
0.96

1.14–2.05
1.25–2.97
0.57–1.64

0.00458
0.00264
1.00000

Parasitemia >20,000/l
± fever, anemia
With fever¶
With anemia#

55
23
20

1.33
0.56
0.48

81
49
18

2.27
1.37
0.50

1.71
2.45
1.04

1.21–2.40
1.50–4.05
0.55–1.97

0.00249
0.00022
1.00000

Parasitemia >50,000/l
± fever, anemia
With fever¶
With anemia#

18
10
7

0.44
0.24
0.17

53
37
10

1.48
1.04
0.28

3.36
4.43
1.65

2.00–5.82
2.13–8.61
0.63–4.35

0.00000
0.00001
0.33789

Endpoint

Any parasitemia
± fever, anemia
With fever¶
With anemia#

* Outcomes per person-year.
† The ratio of wet season rates over dry season.
‡ The confidence intervals (CIs) are Sato limits.
§The P value is Fisher’s exact (two-tail) chi-square.
¶ Fever is defined as an axillary temperature >99°F.
# Anemia is defined as a hemoglobin level <8 g/dl.

Cumulative incidence. Figure 4 shows the cumulative incidence of all parasitemias and parasitemias > 20,000/l in the
two cohorts. The cumulative incidence of parasitemia after
radical cure increased more slowly during the first three

weeks of risk in the wet season cohort compared with the
same period in the dry season cohort (cumulative incidence
⳱ 0.19 versus 0.04; P ⳱ 0.0025). The 20-week cumulative
incidence of parasitemia in the dry season cohort reached a
plateau at 0.76 at the end of 12 weeks, leaving about onequarter of the cohort virtually risk-free for the remaining two
months of follow-up. In contrast, the wet season cohort
reached a plateau cumulative incidence of 0.93 at the end of
10 weeks. During the remaining 10 weeks of presumably high
risk, only an additional 3% of subjects became infected. A
total of six subjects remained free of infection throughout the
study, and these accounted for the 3.5% risk of not being
infected. The 20-week cumulative incidence of infection by P.
falciparum was 96.5%. The risk of parasitemia < 20,000/l
peaked at approximately 25% in both cohorts at about the
same time, at the end of nine weeks.
DISCUSSION

FIGURE 4. Cumulative incidence of any parasitemia by Plasmodium falciparum in infants and small children during the wet (solid
circles) and dry (hollow circles) seasons, along with cumulative incidence of high density parasitemia (>20,000/l) in the wet (solid triangles) and dry (hollow triangles) seasons in the Kassena-Nankana
District of northern Ghana.

Intense transmission of P. falciparum occurred from May
to February in the Kassena-Nankana District of northern
Ghana. The incidence density of infection decreased moderately during the dry season that commenced in October.
Transmission abruptly dropped to very low levels only during
the last two to three months of the dry season (Figure 4). No
significant differences appeared among children of any age in
the dry and wet season cohorts with respect to geometric
mean density of parasitemia at either enrollment or first parasitemia (Table 2A and B). Appreciable differences between
seasons appeared only when the data were stratified by parasite count and fever (Table 3). The relative risk of parasitemia
with fever at any density, > 5,000/l, > 10,000/l, > 20,000/l,
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and > 50,000/l for the wet season cohort relative to the dry
season cohort was 1.66, 1.92, 1.89, 2.45, and 4.33, respectively.
Risk of parasitemia with fever increased in proportion to the
density of parasitemia during the wet season. In both cohorts,
the incidence density of these parasitemia outcomes diminished sharply with increasing counts. The outcomes of greatest relative risk during the wet season represented low frequency events, e.g., parasitemia > 50,000/l with fever was
four times more likely to occur during the wet season, but
occurred less frequently than the lower parasitemia levels
with fever (1.04 versus 1.71 events per person-year).
Despite the relatively subtle parasitologic and clinical distinctions between the dry and wet season cohorts, the statistical power of vaccine trials applying endpoints of high parasitemia and fever would be enhanced by execution framed to
capture wet season risks. The example of risk of parasitemia
> 50,000/l with fever measured in these studies best illustrates this point. If one assumes a vaccine efficacy of 85%, and
the operational requirement to have an 80% probability of
having a 95% CI that excludes 70% (i.e., the lower limit of
acceptability for efficacy), then the dry season incidence rate
of 0.24 events per person year for this outcome demands a
sample size of 2,055. Applying the same parameters to the
1.04 events per person year incidence rate in the wet season
gives a sample size estimate of just 363 subjects. Relatively
subtle distinctions in seasonal end point incidence densities
may profoundly impact sample size requirements in intervention trials.
Anemia is an important feature of morbidity caused by
malaria in the Kassena-Nankana District. The infants and
young children in these studies showed dramatic distinctions
with respect to the prevalence of severe anemia as seen at
enrollment at the end of the dry and wet seasons.10 In effect,
an epidemic of severe malarial anemia occurred in these children as the wet season progressed: apparently starting at 1%
in May and increasing to 24% in October. Given the fact that
we have now documented that intense transmission continues
at least to February, the prevalence of severe anemia may
even worsen relative to the 25% rate measured in October.
The relatively brief respite in transmission between February
and May appeared sufficient to allow recovery of most severe
anemia to above the 6.0 g/dl level. The work reported here
and by Koram and others10 demonstrates the need for longitudinal studies of seasonal risk of severe anemia in northern
Ghana.
The relatively low risk of anemia among our subjects with
first parasitemia, and the absence of any differences between
the dry and wet season risks of anemia is a product of the
experimental design. Chronic infection causes anemia in malaria.13,14 Measuring the incidence density of infection necessitated radical cure and, thus, the interruption of chronic parasitemia. Moreover, we could not enroll the 25% of screened
children with severe anemia, so that children in the dry and
wet season cohorts began radical cure with similar anemia
profiles, parasitologic features, and chemotherapy. Thus, it
was not surprising that the first parasitemia of the dry season
had no less risk of anemia compared with that in the wet
season. This study has demonstrated that intervention trials
applying an endpoint that includes severe anemia should allow for a chronic course of parasitemia.
The failure of 2.2% of the subjects in the wet season cohort
to develop parasitemia (accounting for a 3.5% residual risk)
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raises potentially important questions. Given the 10-week
plateau in the face of intense transmission, it is difficult to
assign these residual aparasitemic subjects to chance. These
children were somehow protected. Unknown genetic factors
may have precluded parasitemia in these children, e.g. HLA
or cytokine promoter alleles.15,16 However, in an adult cohort
from the same gene pools and treated and followed through
the wet season in the same manner,17 all developed parasitemia. Possible explanations for the minority of child subjects
failing to develop parasitemia include consistently applied
and extraordinarily effective protective measures by the family (e.g., mosquito netting, repellants, or antimalarials), and
genetic or immunogenetic factors that protect children but
not adults from parasitemia.
The geometric mean parasitemia densities at enrollment
were significantly lower than at first parasitemia post-radical
cure. At enrollment, the dry and wet season cohorts had geometric mean densities of 1,112 and 1,099/l, whereas these
densities were 3,310 and 3,056/l at first parasitemia (P <
0.001 for each). Many explanations for these differences are
possible, but we consider the effect of radical cure as most
likely. Although it is difficult to rule out drug-mediated interference with immune effectors that limit parasite densities
as an explanation, we instead favor diminished effectiveness
of premunition as a consequence of eradication of parasitemia by radical curative therapy. Premunition is the protection from heavy parasite burdens imbued by lesser parasite
burdens. We think the elimination of chronic, relatively lowgrade parasitemia may have established susceptibility to
acute, relatively high-grade parasitemia. This carries important implications with regard to experimental design in intervention studies and to control strategies aimed at delivering
effective therapies in holoendemic Africa. Studies designed to
address this important question should be carried out.
In summary, these studies have documented intense malaria transmission with an incidence density between five and
seven infections/person-year through most of the year among
children 6–24 months old living in the Kassena-Nankana District of northern Ghana. A period of 2–3 months at the end of
the dry season had very low risk of infection, and marked a
dramatic decrease in the prevalence of severe anemia. Postradical cure infections carried risk of relatively high-density
parasitemia during dry or wet seasons.
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